Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer

Cancer

Volumn 118, Issue 15, 2012, Pages 3703-3709

  Hyman, David M ^a   Zhou, Qin ^a   Iasonos, Alexia ^a   Grisham, Rachel N ^a   Arnold, Angela G ^a   Phillips, Mary F ^a   Bhatia, Jasmine ^a   Levine, Douglas A ^a   Aghajanian, Carol ^a   Offit, Kenneth ^a   Barakat, Richard R ^a   Spriggs, David R ^a   Kauff, Noah D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

BRCA1; BRCA2; ovarian cancer; poly(ADP ribose); polymerase inhibitors

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYTOTOXIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CANCER SURVIVOR; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; GENETIC SCREENING; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; OVARY CANCER; OVERALL SURVIVAL; PATIENT REFERRAL; PERITONEUM CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEROUS OVARIAN CANCER; SURVIVAL PREDICTION; UTERINE TUBE TUMOR;

ADULT; AGED; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS;

EID: 84864146390     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26655     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.
2. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005; 104: 2807-2816.
3. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001; 68: 700-710.
4. Press JZ, De Luca A, Boyd N, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities [serial online]. BMC Cancer. 2008; 8: 17.
5. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL,. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002; 94: 1365-1372.
6. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998; 62: 676-689.
7. Chen S, Parmigiani G,. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007; 25: 1329-1333.
8. Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, et al. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet. 2000; 355: 2015-2020.
9. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 2000; 283: 2260-2265.
10. Jazaeri AA, Yee CJ, Sotiriou C, Brantley KR, Boyd J, Liu ET,. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst. 2002; 94: 990-1000.
11. Aida H, Takakuwa K, Nagata H, et al. Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1. Clin Cancer Res. 1998; 4: 235-240.
12. Ben David Y, Chetrit A, Hirsh-Yechezkel G, et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol. 2002; 20: 463-466.
13. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY,. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer. 2003; 97: 2187-2195.
14. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S,. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol. 2008; 26: 20-25.
15. Gallagher DJ, Konner JA, Bell-McGuinn KM, et al. Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. Ann Oncol. 2011; 22: 1127-1132.
16. Pal T, Permuth-Wey J, Kapoor R, Cantor A, Sutphen R,. Improved survival in BRCA2 carriers with ovarian cancer. Fam Cancer. 2007; 6: 113-119.
17. Rubin SC, Benjamin I, Behbakht K, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med. 1996; 335: 1413-1416.
18. Tan DS, Rothermundt C, Thomas K, et al. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol. 2008; 26: 5530-5536.
19. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474: 609-615.
20. Scheuer L, Kauff N, Robson M, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol. 2002; 20: 1260-1268.
21. Anderson JR, Cain KC, Gelber RD,. Analysis of survival by tumor response. J Clin Oncol. 1983; 1: 710-719.
22. Kutner MH, Nachtsheim C, Neter J,. Applied Linear Regression Models. 4th ed. New York: McGraw-Hill/Irwin; 2004.
23. Koonings PP, Campbell K, Mishell DR Jr, Grimes DA,. Relative frequency of primary ovarian neoplasms: a 10-year review. Obstet Gynecol. 1989; 74: 921-926.
24. Sandhu SK, Wenham RM, Wilding G, et al. First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers [abstract]. J Clin Oncol. 2010; 28 (7S). Abstract 3001.
25. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434: 917-921.
26. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009; 361: 123-134.
27. Hennessy BT, Timms KM, Carey MS, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly(ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol. 2010; 28: 3570-3576.